Crinetics Pharmaceuticals Inc (CRNX) concluded trading on Wednesday at a closing price of $30.50, with 0.48 million shares of worth about $14.65 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -43.16% during that period and on June 18, 2025 the price saw a loss of about -1.13%. Currently the company’s common shares owned by public are about 93.53M shares, out of which, 86.66M shares are available for trading.
Stock saw a price change of -5.66% in past 5 days and over the past one month there was a price change of -1.45%. Year-to-date (YTD), CRNX shares are showing a performance of -40.35% which decreased to -32.72% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $24.10 but also hit the highest price of $62.53 during that period. The average intraday trading volume for Crinetics Pharmaceuticals Inc shares is 937.06K. The stock is currently trading -2.54% below its 20-day simple moving average (SMA20), while that difference is down -2.27% for SMA50 and it goes to -29.18% lower than SMA200.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) currently have 93.53M outstanding shares and institutions hold larger chunk of about 105.00% of that.
The stock has a current market capitalization of $2.86B and its 3Y-monthly beta is at 0.28. It has posted earnings per share of -$3.82 in the same period. It has Quick Ratio of 22.53 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRNX, volatility over the week remained 0.32% while standing at 2.03% over the month.
Stock’s fiscal year EPS is expected to drop by -22.35% while it is estimated to decrease by -3.84% in next year. EPS is likely to grow at an annualized rate of 2.12% for next 5-years, compared to annual growth of -12.11% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stifel on March 25, 2025 offering a Buy rating for the stock and assigned a target price of $60 to it. On February 04, 2025, Wolfe Research Initiated their recommendations, while on January 22, 2025, Jefferies Upgrade their ratings for the stock with a price target of $55. Stock get a Buy rating from Citigroup on March 06, 2024.
